Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study

Çakır, Ömer; Castiglione, Fabio; Tandoğdu, Zafer; Collins, Justin; Alnajjar, Hussain M.; Akers, C.; Albersen, Maarten; Alifrangis, Constantine; Ayres, Benjamin; Brouwer, O.R.; Cullen, Ivor M.; Hawkey, Peter M.; Jakobsen, John; Johansen, Truls E. Bjerklund; Kalejaiye, Odunayo; Kaul, Asheesh; Köves, B.; Kumar, Vivekanandan; Mancini, Mariangela; Mitra, Anita; Parnham, Arie; Pozzi, Edoardo; Protzel, Chris; Sangar, Vijay; Wagenlehner, Florian M. E.; Muneer, Asıf

doi:10.1016/j.urolonc.2020.12.005

Cited by 12 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the low incidence of penile cancers, few resources were invested during the COVID-19 pandemic [ 84 ]. In order to reduce hospital visits during the COVID-19 pandemic, some experts concurred that individuals with penile lesions that are clinically visible malignancies should not obtain a biopsy to confirm the diagnosis before beginning a final course of therapy in order to decrease the frequency of hospital visits [ 85 ]. More crucially, individuals with penile lesions that have a low index of suspicion should not have biopsy but rather should be kept under monitoring.…”

Section: Resultsmentioning

confidence: 99%

Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Background: The aim of this paper is to discuss the impact of COVID-19 on patients with urological malignancies (prostate cancer, bladder and upper tract urothelial cancer, kidney cancer, penile and testicular cancer) and to review the available recommendations reported in the literature. Methods: A review was performed, through the PubMed database, regarding available recommendations reported in the literature, to identify studies examining the impact of COVID-19 on treatment and clinical outcomes (including upstaging, recurrence, and mortality) for uro-oncological patients. Results: The COVID-19 pandemic dramatically changed the urological guidelines and patients’ access to screening programs and follow-up visits. Great efforts were undertaken to guarantee treatments to high-risk patients although follow up was not always possible due to recurrent surges, and patients with lower risk cancers had to wait for therapies. Conclusions: Physically and mentally, uro-oncological patients paid a heavy price during the COVID-19 pandemic. Long term data on the “costs” of clinical decisions made during the COVID-19 pandemic are still to be revealed and analyzed.

show abstract

Section: Resultsmentioning

confidence: 99%

Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Some other initiatives have been developed to obtain a consensus in uro‐oncology diseases using variations of the Delphi consensus methodology. The eUROGEN group achieves 80 consensus statements about the management of penile cancer patients during the COVID‐19 pandemic after four Delphi rounds 13 . A group of international uro‐oncology experts reached a 75 statement consensus after three Delphi rounds in the management of patients who opt for radical prostatectomy during the pandemic 14 …”

Section: Discussionmentioning

confidence: 99%

“…The eUROGEN group achieves 80 consensus statements about the management of penile cancer patients during the COVID-19 pandemic after four Delphi rounds. 13 A group of international uro-oncology experts reached a 75 statement consensus after three Delphi rounds in the management of patients who opt for radical prostatectomy during the pandemic. 14 We have found some limitations.…”

Section: Discussionmentioning

confidence: 99%

Development of a questionnaire set to evaluate adaptations to COVID era: The ICS TURNOVER project (Transition of fUnctional uRology to New COVID ERa)

Hajebrahimi

Lavalle

Arlandis

et al. 2022

Neurourology and Urodynamics

View full text Add to dashboard Cite

Objectives: Coronavirus disease 2019 (COVID-19) pandemic has caused a massive cutdown in outpatient urological investigations, procedures, and interventions. Female and functional urology (FFU) has been probably the most affected subspecialty in urology. Several scientific societies have published guidelines to manage this new situation, providing general recommendations.The aim of this study was to devise a robust questionnaire covering every different aspect of FFU to obtain recommendations on COVID-19 adaptations.Methods: Delphi methodology was adapted to devise the survey questionnaires for male/female lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP), chronic pelvic pain (CPP), and neuro-urological disease.Content validity, face validity, and internal consistence were assessed to establish the final questionnaire. This study was ethically approved by the Local Research Ethics Committee.Results: A total 97, 59, 79, 85, and 84 items for female and male LUTS, POPs, CPP, and neuro-urology respectively were approved by the participants.Content validity over 0.70 was obtained which seemed reasonable content validity scores. Internal consistency obtains values of Cronbach's alpha was between 0.70 and 0.90 which was acceptable. Conclusions:The collective wisdom obtained through a global survey using validated questionnaires covering every different aspect of FFU patient management is necessary. We have developed a robust and validated tool consisting of five questionnaires covering the most prevalent pathologies in FFU.

show abstract

“…Given that many penile cancers present late, and the risk for metastatic spread, pre-operative staging techniques may include inguinal ultrasonography, CT or MRI ( 76 ). The symptoms of penile cancer have led to patient delays in seeking treatment in the era prior to the COVID-19 pandemic, leading to an overall increase in the likelihood of disease progression ( 77 ). Delayed diagnosis of 6 months from a retrospective study noted that 47% of patients presented with locally advanced disease ( 78 ).…”

Section: Clinical Diagnosis Of Gu Cancersmentioning

confidence: 99%

“…In a recent retrospective analysis, early surgical intervention for penile cancer demonstrated 5 year disease specific survival of 61.4% vs 39.5% in those with delayed dissection ( 114 ). Despite potential immunomodulatory effects, consensus guidelines recommend that those patients with advanced or metastatic disease should be considered for neo-adjuvant or adjuvant chemotherapy with or without radiation therapy ( 77 ) ( Figure 2 ). For penile cancers with intermediate risk of progression, surgical treatment may be delayed up to three months, but radiation therapy and brachytherapy should be considered as effective options.…”

Section: Impact Of Covid-19 On Gu Cancer Treatment and Clinical Outcomesmentioning

confidence: 99%

The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease–2019 (COVID-19), a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, has become an unprecedented global health emergency, with fatal outcomes among adults of all ages throughout the world. There is a high incidence of infection and mortality among cancer patients with evidence to support that patients diagnosed with cancer and SARS-CoV-2 have an increased likelihood of a poor outcome. Clinically relevant changes imposed as a result of the pandemic, are either primary, due to changes in timing or therapeutic modality; or secondary, due to altered cooperative effects on disease progression or therapeutic outcomes. However, studies on the clinical management of patients with genitourinary cancers during the COVID-19 pandemic are limited and do little to differentiate primary or secondary impacts of COVID-19. Here, we provide a review of the epidemiology and biological consequences of SARS-CoV-2 infection in GU cancer patients as well as the impact of COVID-19 on the diagnosis and management of these patients, and the use and development of novel and innovative diagnostic tests, therapies, and technology. This article also discusses the biomedical advances to control the virus and evolving challenges in the management of prostate, bladder, kidney, testicular, and penile cancers at all stages of the patient journey during the first year of the COVID-19 pandemic.

show abstract

Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study

Cited by 12 publications

References 26 publications

Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature

Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature

Development of a questionnaire set to evaluate adaptations to COVID era: The ICS TURNOVER project (Transition of fUnctional uRology to New COVID ERa)

The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic

Contact Info

Product

Resources

About